Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. raised its position in Amgen Inc. (NASDAQ:AMGN) by 23.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,033 shares of the medical research company’s stock after purchasing an additional 195 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Amgen were worth $333,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Kovack Advisors Inc. raised its position in Amgen by 23.8% in the first quarter. Kovack Advisors Inc. now owns 3,694 shares of the medical research company’s stock valued at $1,050,000 after purchasing an additional 711 shares during the period. Veracity Capital LLC raised its position in Amgen by 8.2% in the first quarter. Veracity Capital LLC now owns 1,614 shares of the medical research company’s stock valued at $459,000 after purchasing an additional 123 shares during the period. J.W. Cole Advisors Inc. increased its position in shares of Amgen by 2.0% during the first quarter. J.W. Cole Advisors Inc. now owns 9,616 shares of the medical research company’s stock worth $2,726,000 after acquiring an additional 188 shares during the period. Private Advisor Group LLC increased its position in shares of Amgen by 4.1% during the first quarter. Private Advisor Group LLC now owns 51,429 shares of the medical research company’s stock worth $14,622,000 after acquiring an additional 2,010 shares during the period. Finally, SeaBridge Investment Advisors LLC increased its position in shares of Amgen by 2.3% during the first quarter. SeaBridge Investment Advisors LLC now owns 17,252 shares of the medical research company’s stock worth $4,905,000 after acquiring an additional 387 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent research reports. Dbs Bank raised Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Oppenheimer reissued an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Robert W. Baird reissued an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Finally, Barclays increased their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $332.55.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $315.54 on Thursday. The business’s 50 day simple moving average is $324.75 and its 200-day simple moving average is $314.78. The firm has a market capitalization of $169.27 billion, a price-to-earnings ratio of 45.08, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same period in the prior year, the company earned $5.00 EPS. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.85%. Amgen’s payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.